TRex Bio doses first healthy volunteer in trial of atopic dermatitis treatment

Atopic dermatitis is marked by itching, impaired skin barrier function, and rashes. Credit: Kwangmoozaa / Shutterstock.
US-based biotechnology company TRex Bio has begun dosing healthy volunteers in a clinical trial of TRB-061 for atopic dermatitis (AD).

TRB-061 is a tumour necrosis factor receptor 2 (TNFR2) agonist being developed to treat AD, which is also referred to as eczema.